Daewoong Pharmaceutical Co., Ltd (069620.KS)
| Previous Close | 110,500.00 |
| Open | 110,500.00 |
| Bid | 112,600.00 x 0 |
| Ask | 112,700.00 x 0 |
| Day's Range | 110,100.00 - 112,900.00 |
| 52 Week Range | 88,300.00 - 127,600.00 |
| Volume | |
| Avg. Volume | 29,899 |
| Market Cap | 1.297T |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 01, 2024 - May 06, 2024 |
| Forward Dividend & Yield | 600.00 (0.52%) |
| Ex-Dividend Date | Dec 28, 2022 |
| 1y Target Est | 165,000.00 |
PR NewswireDaewoong Pharmaceutical Announces 2023 Financial Results
Daewoong Pharmaceutical (KRX: 069620.KS), a global pharmaceutical company located in Seoul, announced its marvelous financial results for 2023.
PR NewswireDaewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis
Daewoong Pharmaceutical's Bersiporocin (DWN12088) has been recognized as a significant advancement in treating idiopathic pulmonary fibrosis (IPF), a rare and debilitating disease. This first-in-class PRS inhibitor has recently received 'Orphan Drug Designation (ODD)' from the European Medicines Agency (EMA), adding to its earlier designation by the U.S. FDA for both IPF and systemic sclerosis.
PR NewswireCGBio's 'NOVOSIS PUTTY' Receives FDA 'Breakthrough Device Designation,' Accelerate Entry into the US Market
CGBio (CEO Hyun Seung Yu), a Korean company specializing in bio-regenerative medicine, announced on the 2nd that its advanced bone substitute material, "NOVOSIS PUTTY", has been granted 'Breakthrough Device Designation' (BDD) by the U.S. Food and Drug Administration (FDA). This material incorporates recombinant human bone morphogenetic protein 2 (rhBMP-2).
